Replimune to Present at Two Upcoming Investor Conferences
Replimune Group (NASDAQ: REPL) announced that its management will present at two upcoming virtual conferences. The BTIG Virtual Biotechnology Conference is scheduled for August 9, 2021, at 11:00 am ET. The second event, the 2021 Wedbush PacGrow Healthcare Virtual Conference, will include a panel discussion on immuno-oncology challenges on August 11, 2021, at 12:35 pm ET. Replimune is focused on developing oncolytic immune-gene therapies to enhance cancer treatment effectiveness through its Immulytic® platform.
- None.
- None.
WOBURN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:
BTIG Virtual Biotechnology Conference 2021
Date: Monday, August 9, 2021
Presentation Time: 11:00 am ET
2021 Wedbush PacGrow Healthcare Virtual Conference
Panel: For Your IOnly - Progress, Challenges in Immuno-Oncology
Date: Wednesday, August 11, 2021
Presentation Time: 12:35 pm ET
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
Westwicke, an ICR Company
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com
FAQ
What is Replimune Group's stock symbol?
When will Replimune present at the BTIG Virtual Biotechnology Conference?
What topics will Replimune discuss at the 2021 Wedbush PacGrow Healthcare Virtual Conference?
What is the purpose of Replimune's Immulytic® platform?
When was Replimune founded?
